VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2015 | ASH 2015 highlights by Prof. Michael Hallek

Michael Hallek, MD from the University of Cologne, Cologne, Germany, provides an overview of main chronic lymphocytic leukemia (CLL) studies being presented at the America Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. Prof. Hallek discusses the new data being presented on venetoclax (ABT-199), a Bcl-2 inhibitor, in CLL patient with 17p deletion or mutated p53, and inhibitors targeting well-known CLL targets, such as Bruton’s tyrosine kinase (BTK) and phosphoinositide 3-kinase (PI3K), as single-agents or in combinations with other therapies.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter